var title_f0_12_192="Digital block finger";
var content_f0_12_192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Finger digital block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To perform a finger web space block, insert the needle into the subcutaneous tissue of the web space at the base of the finger, just distal to the MCP (metacarpal/phalangeal) joint. Slowly advance the needle straight through the web space toward the palmar surface, injecting as the needle is advanced. The black ink line illustrates the likely course of the dorsal digital nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Baldor, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_192=[""].join("\n");
var outline_f0_12_192=null;
var title_f0_12_193="Pulm AVM Brain CT";
var content_f0_12_193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient with an arteriovenous malformation in right lower lobe who developed a stroke",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan of the brain shows a right-sided ischemic stroke in the middle cerebral artery territory.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_193=[""].join("\n");
var outline_f0_12_193=null;
var title_f0_12_194="Systolic pressure variation and pulse pressure variation";
var content_f0_12_194=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F85848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F85848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Systolic pressure variation and pulse pressure variation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Respiratory variations in arterial pressure.",
"    <div class=\"footnotes\">",
"     SPV: systolic pressure variation; PP",
"     <sub>",
"      MAX",
"     </sub>",
"     : pulse pressure maximal; PP",
"     <sub>",
"      MIN",
"     </sub>",
"     : pulse pressure minimal.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Biais M, Ouattara A, Janvier G, Sztark F. Case Scenario: Respiratory variations in arterial pressure for guiding fluid management in mechanically ventilated patients. Anesthesiology 2012; 116:1354. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_194=[""].join("\n");
var outline_f0_12_194=null;
var title_f0_12_195="Aortic regurgitation as heard at the lower left sternal border";
var content_f0_12_195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1048px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/77962/aorllsb_conv.mp4?title=Aortic+regurgitation+as+heard+at+the+lower+left+sternal+border\" style=\"width:458px;height:468px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phonocardiogram of aortic regurgitation as heard at the lower left sternal border",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Carotid artery pulse tracing and phonocardiogram of aortic regurgitation as heard at the fourth left intercostal space. S1 (mitral and tricuspid valve closure) is followed by a short mid systolic ejection murmur resulting from the large stroke volume seen in aortic regurgitation. Following S2 (aortic and pulmonic valve closure) there is a holodiastolic blowing murmur of aortic regurgitation (AR).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_195=[""].join("\n");
var outline_f0_12_195=null;
var title_f0_12_196="Fares technique for shoulder reduction";
var content_f0_12_196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/83572/Fares_shoulder_reduc_video.mp4?title=Fares+technique+for+shoulder+reduction\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fares technique for shoulder reduction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Simon and Sherman, Emergency Orthopedics, 6th edition DVD &copy; Scott Sherman, all rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_196=[""].join("\n");
var outline_f0_12_196=null;
var title_f0_12_197="Cromolyn sodium (nasal): Patient drug information";
var content_f0_12_197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cromolyn sodium (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/27/23987?source=see_link\">",
"     see \"Cromolyn sodium (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/24/35202?source=see_link\">",
"     see \"Cromolyn sodium (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13319698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NasalCrom&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8011994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cromolyn Nasal Spray&reg; [OTC];",
"     </li>",
"     <li>",
"      Rhinaris-CS Anti-Allergic Nasal Mist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701867",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cromolyn sodium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697685",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not helpful in urgent times.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep taking this drug to stop the allergy. Once signs start, this drug will not help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the nose only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11620 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_197=[""].join("\n");
var outline_f0_12_197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319698\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011994\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030391\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030390\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030395\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030396\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030398\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030393\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030394\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030399\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030400\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/27/23987?source=related_link\">",
"      Cromolyn sodium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/24/35202?source=related_link\">",
"      Cromolyn sodium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/3/28723?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/46/17124?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/45/19154?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/12/17605?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/53/29524?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/63/28660?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_12_198="Antihemophilic factor concentrates (human): Drug information";
var content_f0_12_198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Antihemophilic factor concentrates (human): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/24/23940?source=see_link\">",
"    see \"Antihemophilic factor concentrates (human): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/35/14902?source=see_link\">",
"    see \"Antihemophilic factor concentrates (human): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hemofil M;",
"     </li>",
"     <li>",
"      Ko��te&reg;-DVI;",
"     </li>",
"     <li>",
"      Monoclate-P&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hemofil M",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F135744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antihemophilic Agent;",
"     </li>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F135731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hemophilia:",
"     </b>",
"     I.V.: Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL. (General guidelines presented; consult individual product labeling for specific dosing recommendations.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage based on desired factor VIII increase (%):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     To calculate dosage needed based on desired factor VIII increase (%):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Body weight (kg) x 0.5 units/kg x desired factor VIII increase (%) = units factor VIII required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For example:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50 kg x 0.5 units/kg x 30 (% increase) = 750 units factor VIII",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage based on expected factor VIII increase (%):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     It is also possible to calculate the",
"     <b>",
"      expected",
"     </b>",
"     % factor VIII increase:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     (# units administered x 2%/units/kg) divided by body weight (kg) = expected % factor VIII increase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For example:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     (1400 units x 2%/units/kg) divided by 70 kg = 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General guidelines:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor hemorrhage: 10-20 units/kg as a single dose to achieve FVIII plasma level ~20% to 40% of normal. Mild superficial or early hemorrhages may respond to a single dose; may repeat dose every 12-24 hours for 1-3 days until bleeding is resolved or healing achieved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate hemorrhage/minor surgery: 15-25 units/kg to achieve FVIII plasma level 30% to 50% of normal. If needed, may continue with a maintenance dose of 10-15 units/kg every 8-12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Major to life-threatening hemorrhage: Initial dose 40-50 units/kg, followed by a maintenance dose of 20-25 units/kg every 8-12 hours until threat is resolved, to achieve FVIII plasma level 80% to 100% of normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Major surgery: 50 units/kg given preoperatively to raise factor VIII level to 100% before surgery begins. May repeat as necessary after 6-12 hours initially and for a total of 10-14 days until healing is complete. Intensity of therapy may depend on type of surgery and postoperative regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bleeding prophylaxis: May be administered on a regular basis for bleeding prophylaxis. Doses of 24-40 units/kg 3 times/week have been reported in patients with severe hemophilia to prevent joint bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If bleeding is not controlled with adequate dose, test for presence of inhibitor. It may not be possible or practical to control bleeding if inhibitor titers are &gt;10 Bethesda units/mL.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F135740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/35/14902?source=see_link\">",
"      see \"Antihemophilic factor concentrates (human): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F135732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemofil M: ~250 units, ~500 units, ~1000 units,  ~1700 units [contains albumin (human), mouse protein; packaging may contain natural rubber latex]. Supplied with diluent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ko��te&reg;-DVI: ~250 units, ~500 units, ~1000 units [contains albumin (human), aluminum, polysorbate 80]. Supplied with diluent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monoclate-P&reg;: ~250 units, ~500 units, ~1000 units, ~1500 units [contains albumin (human), mouse protein]. Supplied with diluent.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F135717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. over 5-10 minutes (maximum: 10 mL/minute). Infuse Monoclate-P&reg; at 2 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F135716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of hemorrhagic episodes in patients with hemophilia A (classic hemophilia); perioperative management of hemophilia A; can be of significant therapeutic value in patients with acquired factor VIII inhibitors not exceeding 10 Bethesda units/mL",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11595784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Factor VIII may be confused with Factor XIII",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Confusion may occur due to the omitting of  &ldquo;Factor VIII&rdquo; from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F135743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Acute hemolytic anemia, AHF inhibitor development, allergic reactions (rare), anaphylaxis (rare), bleeding tendency increased, blurred vision, chest tightness, chills, fever, headache, hyperfibrinogenemia, jittery feeling, lethargy, nausea, somnolence, stinging at the infusion site, stomach discomfort, tingling, urticaria, vasomotor reactions with rapid infusion, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F135720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F135704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood types A, B, and AB: Contains trace amounts of blood groups A and B isohemagglutinins and when large or frequently repeated doses are given to individuals with blood groups A, B, and AB, the patient should be monitored for signs of progressive anemia and the possibility of intravascular hemolysis should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin:  Products vary by preparation method; final formulations contain human albumin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Hepatitis B vaccination is recommended for all patients. Hepatitis A vaccination is also recommended for seronegative patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Natural rubber latex is a component of Hemofil M packaging.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mouse protein: Hemofil M and Monoclate-P&reg; contain trace amounts of mouse protein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; von Willebrand factor: Products contain naturally-occurring von Willebrand factor for stabilization, however efficacy has not been established for the treatment of von Willebrand disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dose requirements: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6217988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F135722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Safety and efficacy in pregnant women have not been established. Use during pregnancy only if clearly needed. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than nonpregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F135736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Monoclate-P Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 unit (1): $1.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $1.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (1): $1.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500 unit (1): $1.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Hemofil M Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220-400 unit (1): $1.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     401-800 unit (1): $1.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     801-1500 unit (1): $1.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1501-2000 unit (1): $1.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Koate-DVI Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 unit (1): $1.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $1.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (1): $1.41",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F135712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate and blood pressure (before and during I.V. administration); AHF levels prior to and during treatment; in patients with circulating inhibitors, the inhibitor level should be monitored; hematocrit; monitor for signs and symptoms of intravascular hemolysis; bleeding",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F135715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe: Factor level &lt;1% of normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate: Factor level 1% to 5% of normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild: Factor level &gt;5% to &lt;40% of normal",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F135723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aleviate (HK);",
"     </li>",
"     <li>",
"      Antihemophilic Factor (Recombinant) (IL);",
"     </li>",
"     <li>",
"      Benefix (KP);",
"     </li>",
"     <li>",
"      Biostate (HK);",
"     </li>",
"     <li>",
"      Emoclot (TH);",
"     </li>",
"     <li>",
"      Factane (FR);",
"     </li>",
"     <li>",
"      Haemate P (GB, IE);",
"     </li>",
"     <li>",
"      Haemoctin (GB);",
"     </li>",
"     <li>",
"      Haemoctin SDH (IL);",
"     </li>",
"     <li>",
"      Hemofil M (FR);",
"     </li>",
"     <li>",
"      Kogenate (CN, FR, TW);",
"     </li>",
"     <li>",
"      Kogenate FS (CL, CO, CR, EC, GT, HK, HN, ID, IL, MY, NZ, PA, SV);",
"     </li>",
"     <li>",
"      Monoclate P (GB, IE);",
"     </li>",
"     <li>",
"      Octanate (MX);",
"     </li>",
"     <li>",
"      Optivate (GB, IE);",
"     </li>",
"     <li>",
"      Recombinate (AR, AT, AU, BE, BR, CH, DE, DK, EE, FI, FR, IT, NL, NZ, SE);",
"     </li>",
"     <li>",
"      Xyntha (SG, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F135703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protein (factor VIII) in normal plasma which is necessary for clot formation and maintenance of hemostasis; activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F135719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life elimination: Mean: 8-27 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abildgaard CF, Simone JV, Corrigan JJ, et al, &ldquo;Treatment of Hemophilia With Glycine-Precipitated Factor VIII,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1966, 275(9):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/198/abstract-text/5917942/pubmed\" id=\"5917942\" target=\"_blank\">",
"        5917942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berntorp E, &ldquo;Impact of Replacement Therapy on the Evolution of HIV Infection in Hemophiliacs,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 1994, 71(6):678-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/198/abstract-text/7974331/pubmed\" id=\"7974331\" target=\"_blank\">",
"        7974331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lusher JM, &ldquo;Transfusion Therapy in Congenital Coagulopathies,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 1994, 8(6):1167-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/198/abstract-text/7860443/pubmed\" id=\"7860443\" target=\"_blank\">",
"        7860443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manucci PM, &ldquo;Impact of Recombinant Factor VIII on Hemophilia Care,&rdquo;",
"      <i>",
"       Vox Sang",
"      </i>",
"      , 1994, 67(Suppl 3):49-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/198/abstract-text/7975511/pubmed\" id=\"7975511\" target=\"_blank\">",
"        7975511",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nilsson IM, Berntorp E, Lofqvist T, et al, &ldquo;Twenty-Five Years' Experience of Prophylactic Treatment in Severe Haemophilia A and B,&rdquo;",
"      <i>",
"       J Intern Med",
"      </i>",
"      , 1992, 232(1):25-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/198/abstract-text/1640190/pubmed\" id=\"1640190\" target=\"_blank\">",
"        1640190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peterson CW, &ldquo;Treating Hemophilia,&rdquo;",
"      <i>",
"       Am Pharm",
"      </i>",
"      , 1994, NS34(8):57-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White GC, Rosendaal F, Aledort LM, et al, &ldquo;Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2001, 85(3):560.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/198/abstract-text/11307831/pubmed\" id=\"11307831\" target=\"_blank\">",
"        11307831",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8825 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_198=[""].join("\n");
var outline_f0_12_198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135729\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135730\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135744\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135731\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135740\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135732\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673186\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673187\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135714\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135700\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135717\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135716\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595784\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135743\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135720\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135704\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298757\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6217988\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135710\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135722\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135736\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322992\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135712\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135715\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135723\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135703\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135719\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8825\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8825|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/24/23940?source=related_link\">",
"      Antihemophilic factor concentrates (human): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/35/14902?source=related_link\">",
"      Antihemophilic factor concentrates (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_12_199="Epidemiology and pathogenesis of developmental dysplasia of the hip";
var content_f0_12_199=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of developmental dysplasia of the hip",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/12/199/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/12/199/contributors\">",
"     Scott B Rosenfeld, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/12/199/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/12/199/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/12/199/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/12/199/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/12/199/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental dysplasia of the hip (DDH) describes a spectrum of conditions related to the development of the hip in infants and young children. It encompasses abnormal development of the acetabulum and proximal femur and mechanical instability of the hip joint.",
"   </p>",
"   <p>",
"    Newborns often have physiologic laxity of the hip and immaturity of the acetabulum during the first few weeks of life. In most cases, the laxity resolves, and the acetabulum proceeds to develop normally. With assessment of risk factors, serial physical examination of the hips, and appropriate use of imaging, most children with pathologic hips can be correctly diagnosed and treated without long-term sequelae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=see_link\">",
"     \"Treatment and outcome of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typical DDH, which generally occurs in otherwise healthy infants, will be the focus of this topic review. Hip dysplasia and instability also occur in association with other conditions. Teratologic hip dysplasia occurs in association with various syndromes (eg, Ehlers Danlos, Down syndrome, arthrogryposis), and neuromuscular hip dysplasia occurs when there is weakness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spasticity in some or all of the hip muscle groups (eg, in spina bifida or cerebral palsy). The diagnosis and management of teratologic and neuromuscular hip dysplasia differ from the diagnosis and management of hip dysplasia in otherwise healthy infants.",
"   </p>",
"   <p>",
"    The epidemiology and pathogenesis of DDH in otherwise healthy children will be reviewed here. The clinical features, diagnosis, treatment, and outcome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=see_link\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=see_link\">",
"     \"Treatment and outcome of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminology for developmental problems of the hip has changed over time. \"Congenital hip dislocation\" was used at a time when most children were diagnosed after they began walking and the dislocation was assumed to be congenital. \"Developmental dysplasia of the hip\" (DDH) is now the preferred term [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/1\">",
"     1",
"    </a>",
"    ]. \"Developmental\" is preferred to \"congenital\" since the condition is not always present or identifiable at birth and develops during early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. \"Dysplasia\" is preferred to \"dislocation\" because it includes a broader spectrum of changes in the shape and position of the femoral head and acetabulum.",
"   </p>",
"   <p>",
"    Specific terms describing the position, stability, and shape of the hip are defined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dislocation &ndash; There is a complete loss of contact between the femoral head and the acetabulum.",
"     </li>",
"     <li>",
"      Subluxation &ndash; The femoral head is partially outside of the acetabulum but remains in contact.",
"     </li>",
"     <li>",
"      Dislocatable &ndash; The femoral head is reduced (ie, within the acetabulum) at rest, but can dislocate in other positions or with examination maneuvers. This is a hip with instability.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Subluxatable/subluxable",
"      </span>",
"      &ndash; The femoral head is reduced at rest but can be partially dislocated or subluxated with examination maneuvers. This is a hip with mild instability or laxity.",
"     </li>",
"     <li>",
"      Reducible &ndash; The hip is dislocated at rest, but the femoral head can be positioned into the acetabulum with manipulation (generally flexion and abduction).",
"     </li>",
"     <li>",
"      Dysplasia &ndash; Abnormality of the shape of the hip joint (usually shallowness of the acetabulum, involving the superior and anterior margins).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the incidence of developmental dysplasia of the hip (DDH) are quite variable and depend upon the means of detection, the age of the child, and the diagnostic criteria. It is estimated that dislocatable hips and hips with severe or persistent dysplasia occur in 3 to 5 per 1000 children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Historically, the incidence of DDH with dislocation is 1 to 2 per 1000 children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Mild hip instability is more common in newborns, with reported incidence as high as 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/4\">",
"     4",
"    </a>",
"    ]. However, mild instability",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild dysplasia in the newborn period often resolve without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/4,7,9\">",
"     4,7,9",
"    </a>",
"    ]. Infants with mild instability",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild dysplasia in the newborn period should not be included in estimates of incidence; their inclusion results in overestimation.",
"   </p>",
"   <p>",
"    In a prospective study, 9030 infants (18,060 hips) were routinely screened for DDH by physical examination and ultrasonography at one to three days of life [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/4\">",
"     4",
"    </a>",
"    ]. Sonographic abnormalities were detected in 995 hips (representing a sonographic",
"    <em>",
"    </em>",
"    incidence of 5.5 percent). However, on repeat examination at two to six weeks of age with no interval treatment, residual abnormalities were detected in just 90 hips (representing a true DDH incidence of 0.5 percent), which then proceeded to treatment. In other words, 90 percent of newborn hips with clinical or sonographic signs of DDH improved spontaneously before two to six weeks of age. It is our opinion that newborns with clinical or sonographic findings of mild laxity or minimal dysplasia have normal immaturity of hip development and should not be diagnosed with or treated for DDH.",
"   </p>",
"   <p>",
"    The incidence of DDH also varies by race. It is increased in the Lapp and Native American populations (25 to 50 cases per 1000 births) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], and decreased in populations of African and Asian descent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H951392079\">",
"     'Swaddling'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Both hips are involved in 20 percent of patients. Among the unilateral cases, the left hip is affected more often than the right. In a meta-analysis of risk factors for DDH that included ten studies (&gt;247,600 patients), the relative risk for involvement of the left hip was 1.54 (95% CI 1.25-1.90) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/14\">",
"     14",
"    </a>",
"    ]. The preponderance of left-sided cases may be related to the typical left occiput anterior fetal positioning, in which the left hip is forced into adduction against the mother's sacrum [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Limited fetal mobility'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental dysplasia of the hip (DDH) is more common among infants with certain risk factors (eg, female sex, breech position). However, most infants who are diagnosed with DDH are without risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Female sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of DDH in girls is estimated to be 1.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. DDH is two to three times more common in female than in male infants [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/14\">",
"     14",
"    </a>",
"    ]. In a meta-analysis of risk factors for DDH that included 24 studies and &gt;556,000 patients, the relative risk ratio for females was 2.54 (95% CI 2.11-3.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased incidence in girls has been attributed to a transient increase in ligamentous laxity related to increased susceptibility of female infants to the maternal hormone relaxin. However, some studies refute this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased incidence of DDH in girls is difficult to separate from the increased risk of DDH in breech deliveries, which is also more common in girls. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Breech presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Limited fetal mobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any condition in which fetal mobility is limited can increase the risk of DDH. Examples include breech position, oligohydramnios, and firstborn infants (in which the primigravid uterus may create a tighter space for the fetus, limiting mobility) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. In a meta-analysis of risk factors for DDH that included five studies (114,917 patients), the relative risk for first born infants was 1.44 (95% CI 1.12 to 1.86) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased birth weight (&gt;4000 g) is described as a risk factor in some [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/15,19\">",
"     15,19",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/7\">",
"     7",
"    </a>",
"    ], studies. Similarly, multiple-gestation pregnancies have not consistently been found to increase the risk of DDH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Breech presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among conditions that limit fetal mobility, breech presentation is the greatest risk factor for DDH. The absolute risk of DDH is estimated to be 12 percent in breech girls and 2.6 percent in breech boys [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/6\">",
"     6",
"    </a>",
"    ]. In a meta-analysis of risk factors for DDH that included 15 studies (&gt;359,300 patients), the relative risk for breech presentation was 3.75 (95% CI 2.25-6.24) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk is higher in infants with frank breech than with footling breech presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/15,19,23\">",
"     15,19,23",
"    </a>",
"    ]. Recommendations for imaging in infants with breech presentation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\", section on 'Infants with risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased risk of DDH is present regardless of the method of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/14\">",
"     14",
"    </a>",
"    ]. However, decreasing the time spent in the breech position by prelabor cesarean delivery may decrease the risk of DDH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. This was illustrated in a retrospective review that found a decreased rate of DDH among breech infants who were delivered by cesarean delivery before the onset of labor (3.7 percent versus 6.6 percent among those delivered by intrapartum cesarean delivery and 8.1 percent among those delivered vaginally) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who are born with other \"packaging\" problems, including torticollis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], plagiocephaly, and metatarsus adductus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], also have an increased rate of DDH. An association with clubfoot is inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Each of these conditions may be related to abnormal positioning",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limited fetal mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/31\">",
"     31",
"    </a>",
"    ]. The association of these conditions with DDH supports the theory that the \"crowding phenomenon\" plays a role in the pathogenesis of DDH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors appear to play a role in the development of DDH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/32\">",
"     32",
"    </a>",
"    ]. The absolute risk of DDH in infants with a positive family history is estimated to be 4.4 percent in girls and 0.9 percent in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/6\">",
"     6",
"    </a>",
"    ]. In a meta-analysis of risk factors for DDH that included four studies (&gt;14,000 patients), the relative risk for positive family history was 1.39 (95% CI 1.23-1.57) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of 589 patients with DDH, the risk of recurrence in subsequent children was 6 percent when there was one affected child, 12 percent when there was one affected parent, and 36 percent when there was an affected parent and an affected child [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H951392079\">",
"    <span class=\"h2\">",
"     Swaddling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of DDH is increased in populations that use swaddling cloths and cradle boards [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/10,34,35\">",
"     10,34,35",
"    </a>",
"    ]. These practices limit hip mobility and position the hip in adduction and extension, which may play a role in the development of DDH. In an experimental study in rats, traditional swaddling in hip adduction and extension resulted in a greater rate of dislocation and dysplasia than no swaddling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/36\">",
"     36",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics, Pediatric Orthopaedic Society of North America, and International Hip Dysplasia Institute recommend &ldquo;",
"    <a class=\"external\" href=\"file://www.hipdysplasia.org/developmental-dysplasia-of-the-hip/hip-healthy-swaddling/\">",
"     hip-healthy swaddling",
"    </a>",
"    &rdquo;, which consists of allowing ample room for hip and knee flexion and free movement of the legs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal hip joint development depends upon normal contact between the acetabulum and the femoral head promoting mutual induction. Abnormal development is a result of abnormal contact, which may result from multiple genetic and environmental factors (intrauterine and postnatal).",
"   </p>",
"   <p>",
"    By the 11",
"    <sup>",
"     th",
"    </sup>",
"    week of gestation, the hip joint is fully formed. The femoral head is spherical and deeply set within the acetabulum [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the femoral head grows at a faster rate than the acetabulum, so that by the end of gestation the femoral head is less than 50 percent covered by the acetabular roof. During the final four weeks of gestation, the hip is vulnerable to mechanical forces, such as adduction, that direct the femoral head away from the central portion of the acetabulum [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/39\">",
"     39",
"    </a>",
"    ]. Conditions that limit fetal mobility, including breech positioning, accentuate these mechanical forces. This results in eccentric contact between the femoral head and the acetabulum.",
"   </p>",
"   <p>",
"    In the newborn period, ligamentous laxity makes the developing hip susceptible to other external mechanical forces. Positioning with the hips extended (eg, swaddling) can result in eccentric hip joint contact as the femoral head glides within or moves outside of the acetabulum [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/40\">",
"     40",
"    </a>",
"    ]. If these factors persist, abnormal hip joint contact leads to structural anatomic changes. If the femoral head is not deeply seated within the acetabulum, the labrum may become everted and flattened and the ligamentum teres elongated. Abnormal ossification of the acetabulum occurs and a shallow acetabulum develops (",
"    <a class=\"graphic graphic_figure graphicRef58719 \" href=\"UTD.htm?12/19/12607\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/199/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With time, the intraarticular structures hypertrophy, including the labrum with a thickened ridge (neolimbus), ligamentum teres, and fibrofatty tissue (pulvinar). Contractures develop in the iliopsoas and hip adductors, and the inferior capsule is pulled into the empty acetabulum further decreasing the potential for the femoral head to reduce into the acetabulum. A false acetabulum may form where the femoral head contacts the lateral wall of the pelvis above the true acetabulum. The lack of contact between the femoral head and acetabulum inhibits further normal development of the hip joint.",
"   </p>",
"   <p>",
"    With or without full dislocation, the hip can develop dysplastic changes. Most commonly the result is a shallow acetabulum with decreased anterior and lateral coverage of the femoral head. There also can be asphericity of the femoral head, a valgus neck-shaft angle, and persistence of excess femoral anteversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/45/38609?source=see_link\">",
"       \"Patient information: Developmental dysplasia of the hip (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Developmental dysplasia of the hip (DDH) describes a spectrum of conditions related to the development of the hip in infants and young children. The spectrum includes abnormalities of stability",
"      <span class=\"nowrap\">",
"       (dislocation/dislocatability",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       subluxation/subluxatability)",
"      </span>",
"      and abnormalities of shape of the femoral head and acetabulum (dysplasia). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of DDH depends upon the definition, the method of detection, and the age of the child at the time of examination. The incidence of true dislocation is estimated to be 1 to 2 per 1000 newborn infants. Large studies with ultrasonographic screening suggest that up to 40 percent of newborns have laxity or immaturity, but 90 percent of these improve spontaneously. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for DDH include female sex, breech presentation and other conditions associated with limited fetal mobility, and family history. However, most patients who are diagnosed with DDH are without risk factors. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DDH has a multifactorial pathogenesis. Ligamentous laxity predisposes the developing hip to mechanical forces that cause eccentric contact between the femoral head and the acetabulum. Abnormal contact results in abnormal development of the acetabulum and femoral head. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Embryology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Academy of Orthopaedic Surgeons Advisory Statement. \"CDH\" should be \"DDH\". American Academy of Orthopaedic Surgeons, Park Ridge, IL, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/2\">",
"      Garvey M, Donoghue VB, Gorman WA, et al. Radiographic screening at four months of infants at risk for congenital hip dislocation. J Bone Joint Surg Br 1992; 74:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/3\">",
"      Ilfeld FW, Westin GW, Makin M. Missed or developmental dislocation of the hip. Clin Orthop Relat Res 1986; :276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/4\">",
"      Bialik V, Bialik GM, Blazer S, et al. Developmental dysplasia of the hip: a new approach to incidence. Pediatrics 1999; 103:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/5\">",
"      Lehmann HP, Hinton R, Morello P, Santoli J. Developmental dysplasia of the hip practice guideline: technical report. Committee on Quality Improvement, and Subcommittee on Developmental Dysplasia of the Hip. Pediatrics 2000; 105:E57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/6\">",
"      Clinical practice guideline: early detection of developmental dysplasia of the hip. Committee on Quality Improvement, Subcommittee on Developmental Dysplasia of the Hip. American Academy of Pediatrics. Pediatrics 2000; 105:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/7\">",
"      BARLOW TG. EARLY DIAGNOSIS AND TREATMENT OF CONGENITAL DISLOCATION OF THE HIP. Proc R Soc Med 1963; 56:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/8\">",
"      . Diagnosis and treatment of congenital dislocation of the hip hoint in the new-born. J Bone Joint Surg Br 1962; 44-B:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/9\">",
"      Marks DS, Clegg J, al-Chalabi AN. Routine ultrasound screening for neonatal hip instability. Can it abolish late-presenting congenital dislocation of the hip? J Bone Joint Surg Br 1994; 76:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/10\">",
"      Coleman SS. Congenital dysplasia of the hip in the Navajo infant. Clin Orthop Relat Res 1968; 56:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/11\">",
"      GETZ B. The hip joint in Lapps and its bearing on the problem of congenital dislocation. Acta Orthop Scand Suppl 1955; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/12\">",
"      Skirving AP, Scadden WJ. The African neonatal hip and its immunity from congenital dislocation. J Bone Joint Surg Br 1979; 61-B:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/13\">",
"      Hoaglund FT, Kalamchi A, Poon R, et al. Congenital hip dislocation and dysplasia in Southern Chinese. Int Orthop 1981; 4:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/14\">",
"      Ortiz-Neira CL, Paolucci EO, Donnon T. A meta-analysis of common risk factors associated with the diagnosis of developmental dysplasia of the hip in newborns. Eur J Radiol 2012; 81:e344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/15\">",
"      Dunn PM. Perinatal observations on the etiology of congenital dislocation of the hip. Clin Orthop Relat Res 1976; :11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/16\">",
"      Shipman SA, Helfand M, Moyer VA, Yawn BP. Screening for developmental dysplasia of the hip: a systematic literature review for the US Preventive Services Task Force. Pediatrics 2006; 117:e557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/17\">",
"      Screening for the detection of congenital dislocation of the hip. Arch Dis Child 1986; 61:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/18\">",
"      Vogel I, Andersson JE, Uldbjerg N. Serum relaxin in the newborn is not a marker of neonatal hip instability. J Pediatr Orthop 1998; 18:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/19\">",
"      Chan A, McCaul KA, Cundy PJ, et al. Perinatal risk factors for developmental dysplasia of the hip. Arch Dis Child Fetal Neonatal Ed 1997; 76:F94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/20\">",
"      R&uuml;hmann O, Lazovi�� D, Bouklas P, et al. Ultrasound examination of neonatal hip: correlation of twin pregnancy and congenital dysplasia. Twin Res 2000; 3:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/21\">",
"      Bielski RJ, Gesell MW, Teng AL, et al. Orthopaedic implications of multiple gestation pregnancy with triplets. J Pediatr Orthop 2006; 26:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/22\">",
"      Barr LV, Rehm A. Should all twins and multiple births undergo ultrasound examination for developmental dysplasia of the hip?: A retrospective study of 990 multiple births. Bone Joint J 2013; 95-B:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/23\">",
"      Lowry CA, Donoghue VB, O'Herlihy C, Murphy JF. Elective Caesarean section is associated with a reduction in developmental dysplasia of the hip in term breech infants. J Bone Joint Surg Br 2005; 87:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/24\">",
"      Hummer CD, MacEwen GD. The coexistence of torticollis and congenital dysplasia of the hip. J Bone Joint Surg Am 1972; 54:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/25\">",
"      Tien YC, Su JY, Lin GT, Lin SY. Ultrasonographic study of the coexistence of muscular torticollis and dysplasia of the hip. J Pediatr Orthop 2001; 21:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/26\">",
"      Walsh JJ, Morrissy RT. Torticollis and hip dislocation. J Pediatr Orthop 1998; 18:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/27\">",
"      JACOBS JE. Metatarsus varus and hip dysplasia. Clin Orthop 1960; 16:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/28\">",
"      Kumar SJ, MacEwen GD. The incidence of hip dysplasia with metatarsus adductus. Clin Orthop Relat Res 1982; :234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/29\">",
"      Westberry DE, Davids JR, Pugh LI. Clubfoot and developmental dysplasia of the hip: value of screening hip radiographs in children with clubfoot. J Pediatr Orthop 2003; 23:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/30\">",
"      Perry DC, Tawfiq SM, Roche A, et al. The association between clubfoot and developmental dysplasia of the hip. J Bone Joint Surg Br 2010; 92:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/31\">",
"      Pazonyi I, Kun A, Czeizel A. Congenital postural deformity association. Acta Paediatr Acad Sci Hung 1982; 23:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/32\">",
"      Hoaglund FT, Healey JH. Osteoarthrosis and congenital dysplasia of the hip in family members of children who have congenital dysplasia of the hip. J Bone Joint Surg Am 1990; 72:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/33\">",
"      Wynne-Davies R. Acetabular dysplasia and familial joint laxity: two etiological factors in congenital dislocation of the hip. A review of 589 patients and their families. J Bone Joint Surg Br 1970; 52:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/34\">",
"      Abd el-Kader Shaheen M. Mehad: the Saudi tradition of infant wrapping as a possible aetiological factor in congenital dislocation of the hip. J R Coll Surg Edinb 1989; 34:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/35\">",
"      Kremli MK, Alshahid AH, Khoshhal KI, Zamzam MM. The pattern of developmental dysplasia of the hip. Saudi Med J 2003; 24:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/36\">",
"      Wang E, Liu T, Li J, et al. Does swaddling influence developmental dysplasia of the hip?: An experimental study of the traditional straight-leg swaddling model in neonatal rats. J Bone Joint Surg Am 2012; 94:1071.",
"     </a>",
"    </li>",
"    <li>",
"     Price CT, Schwend RM. Improper swaddling a risk factor for developmental dysplasia of the hip. AAP News 2011; 32:11. file://aapnews.aappublications.org/content/32/9/11.1.full (Accessed on September 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/38\">",
"      R&aacute;lis Z, McKibbin B. Changes in shape of the human hip joint during its development and their relation to its stability. J Bone Joint Surg Br 1973; 55:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/39\">",
"      Ponseti IV. Growth and development of the acetabulum in the normal child. Anatomical, histological, and roentgenographic studies. J Bone Joint Surg Am 1978; 60:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/40\">",
"      MASSIE WK, HOWORTH MB. Congenital dislocation of the hip. III. Pathogenesis. J Bone Joint Surg Am 1951; 33:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/199/abstract/41\">",
"      Dunn PM. The anatomy and pathology of congenital dislocation of the hip. Clin Orthop Relat Res 1976; :23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6287 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_199=[""].join("\n");
var outline_f0_12_199=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Female sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Limited fetal mobility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Breech presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H951392079\">",
"      Swaddling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EMBRYOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6287\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6287|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/19/12607\" title=\"figure 1\">",
"      Hip dislocation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=related_link\">",
"      Clinical features and diagnosis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/45/38609?source=related_link\">",
"      Patient information: Developmental dysplasia of the hip (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=related_link\">",
"      Treatment and outcome of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_12_200="Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults";
var content_f0_12_200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/12/200/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/12/200/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/12/200/contributors\">",
"     John Anastasi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/12/200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/12/200/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/12/200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/12/200/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/12/200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute myeloid leukemia (AML) refers to a group of hematopoietic neoplasms involving cells committed to the myeloid lineage. Acute promyelocytic leukemia (APL) is a biologically and clinically distinct variant of AML. APL was classified as AML-M3 in the older French-American-British (FAB) classification system and is currently classified as acute promyelocytic leukemia with t(15;17)(q24.1;q21.1);PML-RARA in the WHO classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39720?source=see_link\">",
"     \"Classification of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    APL represents a medical emergency with a high rate of early mortality, often due to hemorrhage from a characteristic coagulopathy. It is critical to start treatment with a differentiation agent (eg, all-trans retinoic acid) without delay as soon as the diagnosis is suspected based upon cytologic criteria, and even before definitive cytogenetic or molecular confirmation of the diagnosis has been made.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and prognosis of APL in adults will be reviewed here. The following other topics are covered separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Molecular biology of APL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=see_link\">",
"       \"Molecular biology of acute promyelocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of APL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12888?source=see_link\">",
"       \"Treatment of relapsed or refractory acute promyelocytic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical features, diagnosis, and prognosis of AML in adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link\">",
"       \"Prognosis of acute myeloid leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link\">",
"       \"Cytogenetics in acute myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on geographic variations, APL accounts for 5 to 20 percent of cases of AML; there appear to be approximately 600 to 800 new cases per year in the United States (US) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the US, incidence rates for AML are slightly higher among Caucasians when compared with Blacks or Asian Pacific Islanders [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. In contrast to other subtypes of AML, rates of APL are higher among Hispanics.",
"   </p>",
"   <p>",
"    The age distribution of patients with APL differs from other forms of AML. APL is uncommon in the first decade of life; its incidence increases during the second decade to reach a plateau during early adulthood, and then remains constant until it decreases after age 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/7\">",
"     7",
"    </a>",
"    ]. Incidence does not vary by gender.",
"   </p>",
"   <p>",
"    APL can sometimes occur after cytotoxic therapy for another disease (eg, breast cancer, lymphoma, other solid tumors), especially in association with the use of topoisomerase-II inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/8\">",
"     8",
"    </a>",
"    ]. Therapy-related AML is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H13#H13\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AML in general, and APL in particular, generally present with symptoms related to complications of pancytopenia (ie, anemia, neutropenia, and thrombocytopenia), including weakness and easy fatigability, infections of variable severity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemorrhagic findings such as gingival bleeding, ecchymoses, epistaxis, or menorrhagia. Combinations of these symptoms are common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unique to APL is a presentation with bleeding secondary to disseminated intravascular coagulation, which is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC) is frequently present at diagnosis or occurs soon after the initiation of cytotoxic chemotherapy in patients with APL. This complication constitutes a medical emergency, since, if left untreated, it can cause pulmonary or cerebrovascular hemorrhage in up to 40 percent of patients and a 10 to 20 percent incidence of early hemorrhagic death [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. The risk appears to be higher in patients with the microgranular variant of APL (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Microgranular variant'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which APL leads to DIC, which is often accompanied by secondary fibrinolysis, is incompletely understood. The following three factors may be of primary importance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue factor, which forms a complex with factor VII to activate factors X and IX.",
"     </li>",
"     <li>",
"      Cancer procoagulant, which activates factor X independent of factor VII.",
"     </li>",
"     <li>",
"      Increased annexin II receptor expression on the surface of the leukemic promyelocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/15\">",
"       15",
"      </a>",
"      ]. Annexin II receptor binds plasminogen and its activator, tissue plasminogen activator, increasing plasmin formation by a factor of 60.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The induction of tumor cell differentiation with retinoic acid, plus appropriate supportive therapy, can lead to rapid improvement in the coagulopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Control of coagulopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;APL is characterized by the presence of atypical promyelocytes in the bone marrow and peripheral blood. Promyelocytes are large (usually &gt;20 microns in diameter) myeloid precursors with variable morphology. Often there is a high nucleus to cytoplasmic ratio, fine chromatin, and prominent nucleoli. The cardinal feature of the promyelocyte is the presence of many violet granules in the cytoplasm with either a dense or coarse pattern, often obscuring the nucleus. The cells of APL differ morphologically from those of normal promyelocytes in that they are larger and typically have creased, folded, bilobed, kidney-shaped, or dumb-bell shaped nuclei (",
"    <a class=\"graphic graphic_picture graphicRef82863 \" href=\"UTD.htm?2/11/2224\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three main morphologic variants of APL:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hypergranular form",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypergranular, or \"typical,\" form of APL is the most common variant, accounting for approximately 75 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/16\">",
"     16",
"    </a>",
"    ]. On Wright-stained smears, the cytoplasm of these promyelocytes typically contains densely-packed bright pink, reddish-blue or dark purple granules (",
"    <a class=\"graphic graphic_picture graphicRef82863 \" href=\"UTD.htm?2/11/2224\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef82864 \" href=\"UTD.htm?21/6/21605\">",
"     picture 2",
"    </a>",
"    ). Neoplastic promyelocytes frequently contain Auer rods or occasionally bundles of Auer rods (",
"    <a class=\"graphic graphic_picture graphicRef82865 \" href=\"UTD.htm?10/57/11156\">",
"     picture 3",
"    </a>",
"    ). Cells with the bundles of Auer rods are called \"faggot cells\" as faggot was an Old English term for a bag of sticks (",
"    <a class=\"graphic graphic_picture graphicRef82866 \" href=\"UTD.htm?36/22/37219\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a typical case of the hypergranular form of APL, the malignant promyelocytes usually account for 30 percent or more of the myeloid cells. Sometimes there are also increased blasts, but there are very few cells that mature past the promyelocyte stage of differentiation. The abnormal promyelocytes are usually intensely Sudan black and myeloperoxidase reaction positive. The non-specific esterase reaction is weakly positive in a quarter of cases, but should not be construed as evidence of monocyte differentiation. Monocytes show bright non-specific esterase reactivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Microgranular variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microgranular (hypogranular) variant accounts for approximately 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/17\">",
"     17",
"    </a>",
"    ]. The cells in this variant typically have a bilobed nucleus and no apparent granules on light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef82867 \" href=\"UTD.htm?42/37/43604\">",
"     picture 5",
"    </a>",
"    ). Primary granules are present, however, and are easily demonstrated using electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/18\">",
"     18",
"    </a>",
"    ]. The hypogranular promyelocytes can sometimes be mistakenly identified as being of monocytic origin. However, in contrast to monocytes, the myeloperoxidase or Sudan Blask B reaction is strongly positive, and the non-specific esterase reaction is negative or only weakly positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Variant t(11;17) and other variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cells with the variant translocation t(11;17) tend to have nuclei that are more regular in outline, with an increased number of maturing neutrophils with hypolobulation (ie, acquired Pelger-Huet anomaly). These cases have features intermediate between AML with maturation and APL, with sparser granules, lack of faggot cells, and absence of the typical bilobed nucleus seen in the typical forms of APL [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/16,19,20\">",
"     16,19,20",
"    </a>",
"    ]. The PLZF-RARA fusion protein that is produced in this chromosomal rearrangement shows reduced sensitivity to retinoic acid that cannot be overcome by pharmacologic doses of ATRA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. As such, these cases have been reclassified in the current WHO system as \"AML with a variant RARA translocation\". Other rare variants include APL with translocations t(5;17)(q35;q21) and the fusion gene NPM1-RARA and t(11;17)(q13;q21) with gene fusion NuMA-RARA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=see_link&amp;anchor=H7#H7\">",
"     \"Molecular biology of acute promyelocytic leukemia\", section on 'Variant translocations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, APL cells share certain immunophenotypic features with their normal promyelocytic counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]; they express CD13 and CD33, are partial, weak, or negative for CD34, and do not express or only dimly express HLA-DR and CD11b. In contrast to normal promyelocytes, APL cells express abnormally low levels of CD15 and weak or variable CD117. The hypogranular variant of APL frequently coexpresses CD2, and can sometimes express CD34. Some cases can also show CD56, and this has been reported to be associated with worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, with the caveats noted above, the APL phenotype is considered CD34",
"    <span class=\"nowrap\">",
"     negative/partial",
"    </span>",
"    or weak positive, HLA-DR negative, CD13 positive, CD33 positive, CD11b negative, CD15 weak or negative, CD17",
"    <span class=\"nowrap\">",
"     weak/variable,",
"    </span>",
"    and sometimes CD2 positive and CD56 positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Molecular genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute promyelocytic leukemia with t(15;17)(q24.1;q21.1);PML-RARA is defined by the presence of a reciprocal translocation between the long arms of chromosomes 15 and 17, with the creation of a fusion gene, PML-RARA which links the retinoic acid receptor alpha (RARA) gene on chromosome 17 with the promyelocytic leukemia (PML) gene on chromosome 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=see_link\">",
"     \"Molecular biology of acute promyelocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of importance, some differences exist regarding the precise location of the translocation breakpoints depending upon whether banded chromosomes are studied by light microscopy or the genetic loci by molecular studies. By chromosomal banding the translocation has been noted as t(15;17)(q22;q12), but based on the human genome sequence, the translocation is now believed to be more precisely written as t(15;17)(q24.1;q21.1).",
"   </p>",
"   <p>",
"    The genetic abnormality may be detected using the following techniques, each of which has advantages and disadvantages [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/5\">",
"     5",
"    </a>",
"    ]. Bone marrow samples are preferred for each technique:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Conventional karyotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;This method is highly specific, and an essential part of the standard workup, but it is time-consuming, usually taking approximately two days for results. Cryptic rearrangements leading to PML-RARA fusion will be missed (false negatives). However, rare molecular subtypes of APL, such as t(11;17), t(5;17), and other additional coexistent cytogenetic abnormalities can be detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fluorescence in situ hybridization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluorescence in situ hybridization (FISH) for the",
"    <span class=\"nowrap\">",
"     PML/RARA",
"    </span>",
"    fusion is less expensive and quicker than conventional cytogenetics. The sensitivity varies depending upon the probe used. FISH does not provide information about the PML-RARA isoform detected and therefore cannot be used for the molecular monitoring of residual disease. FISH can be performed usually within 24 hours or, in some instances, in an even shorter time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Reverse transcriptase polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reverse transcriptase polymerase chain reaction (RT-PCR) for PML-RARA RNA is considered by many to be the current \"gold standard\" method for confirming the diagnosis of APL. RT-PCR also provides information on the PML breakpoint location, which can be used for monitoring minimal residual disease. However, RT-PCR has a long turn-around time (approximately two days) and can have both false positives (contamination artifacts) and false negatives (due to poor RNA yield). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Anti-PML monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunostaining with anti-PML monoclonal antibodies is a somewhat specific test that can be performed in as little as two to four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/25\">",
"     25",
"    </a>",
"    ]. APL demonstrates a microspeckled nuclear staining pattern with nucleolar exclusion that differs from the discrete larger and fewer nuclear dots seen in normal cells and other forms of AML (",
"    <a class=\"graphic graphic_picture graphicRef82868 \" href=\"UTD.htm?30/24/31119\">",
"     picture 6",
"    </a>",
"    ). Sometimes, however, the staining pattern of non-APL cases can be difficult to interpret.",
"   </p>",
"   <p>",
"    Alternative fusion genes have been described that result in leukemias that would now be classified as \"AML with a variant RARA translocation.\" This distinction has been made primarily because patients with t(11;17) do not respond to therapy with differentiation agents (eg, ATRA). The response of cases with other fusion genes to differentiation therapy is varied. The most common variant translocations are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      t(11;17)(q23;q21) &mdash;",
"      <span class=\"nowrap\">",
"       PLZF/RARa,",
"      </span>",
"      often CD13+, CD56+",
"     </li>",
"     <li>",
"      t(5;17)(q35;q21) &mdash;",
"      <span class=\"nowrap\">",
"       NPM1/RARa,",
"      </span>",
"      often CD13-, CD56-",
"     </li>",
"     <li>",
"      t(11;17)(q13;q21) &mdash;",
"      <span class=\"nowrap\">",
"       NuMA/RARa",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=see_link&amp;anchor=H7#H7\">",
"     \"Molecular biology of acute promyelocytic leukemia\", section on 'Variant translocations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, additional accompanying acquired mutations in particular genes such as FLT3-ITD (fms-like tyrosine kinase-internal tandem duplications) may be present as well although their prognostic significance for the time being is not certain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link&amp;anchor=H9#H9\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;APL represents a medical emergency with a high rate of early mortality, often due to hemorrhage from a characteristic coagulopathy. It is critical to start treatment with a differentiation agent (eg, tretinoin, also known as all-trans retinoic acid or ATRA) without delay as soon as the diagnosis is suspected based upon cytologic and clinical criteria, and before definitive (cyto)genetic confirmation of the diagnosis has been made. If the diagnosis were not confirmed, ATRA can be discontinued and treatment changed to that used for other types of acute myeloid leukemia (AML). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of APL is suspected by the characteristic morphology of the leukemic cells, immunophenotype, or the presence of severe coagulopathy as described above. Another diagnostic clue is that the non-microgranular form of APL often presents with leukopenia. The diagnosis is then confirmed by the identification of the PML-RARA fusion gene or the associated chromosomal translocation. While all available diagnostic tools should be utilized, a request for an expedited FISH analysis looking for PML-RARA generally provides the fastest diagnostic result. This genetic confirmation serves to differentiate APL from other forms of acute leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without treatment, APL is the most malignant form of AML with a median survival of less than one month. However, with modern therapy, APL is associated with the highest proportion of patients who are presumably cured of their disease. Despite the overall good prognosis for this group of patients, there is heterogeneity in this population. Patients younger than age 30 years and those who present with a white blood cell count less than 10 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (10,000/microL)",
"    </span>",
"    have superior event-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/26\">",
"     26",
"    </a>",
"    ]. In contrast to other types of AML, age over 60 years is not a predictor of poor results in APL [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43768?source=see_link&amp;anchor=H6273162#H6273162\">",
"     \"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults\", section on 'Outcomes in older compared with younger patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a multivariate analysis of 217 patients with newly-diagnosed PML-RARA-positive APL treated in the Italian GIMEMA and the Spanish PETHEMA trials, adverse risk factors were a total white blood cell (WBC) count greater than 10 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (10,000/microL)",
"    </span>",
"    and a platelet count less than or equal to 40 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (40,000/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/28\">",
"     28",
"    </a>",
"    ]. Using these two parameters, three prognostic categories could be distinguished, with the following estimated probabilities of three-year relapse-free survival (RFS):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk &mdash; WBC &le;10 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      and platelets &gt;40 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L;",
"      </span>",
"      RFS 98 percent",
"     </li>",
"     <li>",
"      Intermediate &mdash; WBC &le;10 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      and platelets &le;40 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L;",
"      </span>",
"      RFS 89 percent",
"     </li>",
"     <li>",
"      High risk &mdash; WBC &gt;10 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L;",
"      </span>",
"      RFS 70 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These three risk groups originally proposed by the PETHEMA group can be collapsed into two groups based entirely on the WBC count (&lt; or",
"    <span class=\"nowrap\">",
"     &gt;10,000/microL",
"    </span>",
"    at diagnosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/29\">",
"     29",
"    </a>",
"    ]. That is, the platelet count is not necessary to distinguish a",
"    <span class=\"nowrap\">",
"     low/intermediate",
"    </span>",
"    risk group when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    is used as early consolidation treatment.",
"   </p>",
"   <p>",
"    When adjusted for the white blood cell count",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the original PETHEMA relapse score described above, patients with the microgranular variant of APL appear to have a similar outcome to those with classical morphology when treated with regimens that incorporate ATRA and anthracyclines.",
"   </p>",
"   <p>",
"    Up to 40 percent of patients will have chromosomal abnormalities in addition to t(15;17). There is no evidence that additional cytogenetic abnormalities or molecular aberrations (eg, FLT3-ITD gene mutations) have an adverse effect on prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. In two large studies of patients treated with an anthracycline plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    or with all-trans retinoic acid (ATRA) and chemotherapy, additional chromosomal abnormalities had no impact on prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/12/200/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Internal tandem duplications in the Fms-like tyrosine kinase-3 receptor (FLT-3-ITD) gene are frequently seen in APL. They are associated with an increased white blood cell count at diagnosis but do not add obvious independent prognostic value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link&amp;anchor=H10#H10\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'FLT3 gene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    Acute promyelocytic leukemia (APL) represents a medical emergency with a high rate of early mortality. It is necessary to start treatment without delay as soon as the diagnosis is suspected based upon cytologic criteria (morphology, cytochemical reactions, and flow cytometric results), and before definitive (cyto)genetic confirmation of the diagnosis has been made. Patients with APL commonly present with symptoms related to complications of pancytopenia including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weakness and easy fatigue (due to anemia)",
"     </li>",
"     <li>",
"      Infections of variable severity (due to neutropenia)",
"     </li>",
"     <li>",
"      Hemorrhage (due to thrombocytopenia or disseminated intravascular coagulation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disseminated intravascular coagulation, which is very often present at diagnosis of APL, requires emergent therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Disseminated intravascular coagulation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Control of coagulopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    APL is characterized by the presence of atypical promyelocytes in the peripheral blood and bone marrow. These cells are typically large with a creased, folded, or bilobed nucleus and cytoplasm filled with bright pink, reddish-blue or dark purple granules (",
"    <a class=\"graphic graphic_picture graphicRef82863 \" href=\"UTD.htm?2/11/2224\">",
"     picture 1",
"    </a>",
"    ). One-quarter of patients will have a microgranular variant where the granules are not as pronounced. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Morphology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    APL cells typically express CD13 and CD33, are usually negative or partially or weakly positive for CD34, and do not express or only dimly express CD15, CD117, HLA-DR, and CD11b. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Immunophenotype'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of APL is confirmed by the identification of the PML-RARA fusion gene, the associated translocation by conventional cytogenetics, fluorescence in situ hybridization (FISH), or the reverse transcriptase polymerase chain reaction (RT-PCR) product. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Molecular genetics'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/2\">",
"      Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/3\">",
"      Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/4\">",
"      Matasar MJ, Ritchie EK, Consedine N, et al. Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. Eur J Cancer Prev 2006; 15:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/5\">",
"      Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/6\">",
"      Chen Y, Kantarjian H, Wang H, et al. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer 2012; 118:5811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/7\">",
"      Vickers M, Jackson G, Taylor P. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia 2000; 14:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/8\">",
"      Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/9\">",
"      Warrell RP Jr, de Th&eacute; H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/10\">",
"      Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/11\">",
"      Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/12\">",
"      Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/13\">",
"      Rodeghiero F, Avvisati G, Castaman G, et al. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/14\">",
"      Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012; 156:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/15\">",
"      Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/16\">",
"      Sainty D, Liso V, Cant&ugrave;-Rajnoldi A, et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood 2000; 96:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/17\">",
"      McKenna RW, Parkin J, Bloomfield CD, et al. Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant. Br J Haematol 1982; 50:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/18\">",
"      Larson RA, Kondo K, Vardiman JW, et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/19\">",
"      Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995; 85:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/20\">",
"      Grimwade D, Biondi A, Mozziconacci MJ, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Fran&ccedil;ais de Cytog&eacute;n&eacute;tique H&eacute;matologique, Groupe de Fran&ccedil;ais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action \"Molecular Cytogenetic Diagnosis in Haematological Malignancies\". Blood 2000; 96:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/21\">",
"      Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93:3167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/22\">",
"      Guidez F, Ivins S, Zhu J, et al. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91:2634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/23\">",
"      Montesinos P, Ray&oacute;n C, Vellenga E, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 2011; 117:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/24\">",
"      Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/25\">",
"      Dimov ND, Medeiros LJ, Kantarjian HM, et al. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer 2010; 116:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/26\">",
"      Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/27\">",
"      Latagliata R, Avvisati G, Lo Coco F, et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged &gt; 60 years. Ann Oncol 1997; 8:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/28\">",
"      Sanz MA, Lo Coco F, Mart&iacute;n G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/29\">",
"      Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116:3751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/30\">",
"      Hiorns LR, Swansbury GJ, Mehta J, et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997; 96:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/31\">",
"      Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/32\">",
"      Slack JL, Arthur DC, Lawrence D, et al. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol 1997; 15:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/12/200/abstract/33\">",
"      De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000; 111:801.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4527 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_200=[""].join("\n");
var outline_f0_12_200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hypergranular form",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Microgranular variant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Variant t(11;17) and other variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Conventional karyotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fluorescence in situ hybridization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Reverse transcriptase polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Anti-PML monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4527\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4527|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/11/2224\" title=\"picture 1\">",
"      Typical hypergranular APL peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/6/21605\" title=\"picture 2\">",
"      APL bone marrow aspirate I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/57/11156\" title=\"picture 3\">",
"      APL bone marrow aspirate II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/22/37219\" title=\"picture 4\">",
"      APL bone marrow aspirate III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/37/43604\" title=\"picture 5\">",
"      Microgranular APL variant peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/24/31119\" title=\"picture 6\">",
"      PML monoclonal antibody staining",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39720?source=related_link\">",
"      Classification of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17976?source=related_link\">",
"      Molecular biology of acute promyelocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43768?source=related_link\">",
"      Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12888?source=related_link\">",
"      Treatment of relapsed or refractory acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_12_201="Amphotericin B (conventional): Pediatric drug information";
var content_f0_12_201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amphotericin B (conventional): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"    see \"Amphotericin B (conventional): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/30/37348?source=see_link\">",
"    see \"Amphotericin B (conventional): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7254335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fungizone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11432526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet&reg;, Amphotec&reg;, AmBisome&reg;) and conventional amphotericin B for injection; conventional amphotericin B for injection doses should not exceed 1.5 mg/kg/day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      General dosing, susceptible infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Maintaining a sodium intake of &gt;4 mEq/kg/day in premature neonates may reduce amphotericin B-associated nephrotoxicity (Turcu, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 0.5 mg/kg/dose once daily. The daily dose can then be gradually increased, usually in 0.25 mg/kg increments on each subsequent day until the desired daily dose is reached; maximum daily dose: 1.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ; in critically ill patients, more rapid dosage acceleration (up to 0.5 mg/kg increments on each subsequent day) may be warranted",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 0.25-1 mg/kg/dose once daily; infuse over 2-6 hours; rapidly progressing disease may require short-term use of doses up to 1.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ; once therapy has been established, amphotericin B can be administered on an every-other-day basis at 1-1.5 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Irrigation, bladder:",
"     </b>",
"     Limited data available: 50",
"     <b>",
"      mcg",
"     </b>",
"     /mL solution, administered as either a continuous irrigation or as an intermittent irrigation 3 times per day with a dwell time of 60-90 minutes; dosing based on two case reports in neonates [PNA at treatment: 3 weeks; 3 months (PCA: 42 weeks)] (Ku, 2004; Martinez-Pajares, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intrathecal, intraventricular, or intracisternal (preferably into the lateral ventricles through a cisternal Ommaya reservoir): Limited data available; some dosing based on experience in older pediatric patients: 25-100",
"     <b>",
"      mcg",
"     </b>",
"     every 48-72 hours; increase to 500",
"     <b>",
"      mcg",
"     </b>",
"     as tolerated (Chiou, 1994; Murphy; 2000;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Blastomycosis",
"      </i>",
"      , treatment:",
"     </b>",
"     I.V.: 1 mg/kg/dose once daily (Chapman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Candidiasis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Invasive, treatment: I.V.: 1 mg/kg/dose once daily for at least 3 weeks (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Urinary tract infections, asymptomatic (high-risk patients); treatment: I.V.: 1 mg/kg/dose once daily (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Urologic procedures; prophylaxis: I.V.: 0.3-0.6 mg/kg/dose once daily for several days before and after procedure (Pappas, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"      see \"Amphotericin B (conventional): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet&reg;, Amphotec&reg;, AmBisome&reg;) and conventional amphotericin B for injection; conventional amphotericin B for injection doses should not exceed 1.5 mg/kg/day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note: Premedication:",
"     </b>",
"     For patients who experience infusion-related immediate reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: NSAID (with or without diphenhydramine)",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Test dose:",
"     </b>",
"     I.V.: 0.1 mg/kg/dose to a maximum of 1 mg; infuse over 20-60 minutes; an alternative method to the 0.1 mg/kg test dose is to initiate therapy with 0.25 mg/kg amphotericin administered over 6 hours; frequent observation of the patient and assessment of vital signs during the first several hours of the infusion is recommended; many clinicians believe a test dose is unnecessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General dosing, susceptible infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 0.25-0.5 mg/kg/dose once daily; gradually increase daily, usually in 0.25 mg/kg increments until the desired daily dose is reached (maximum  daily dose: 1.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ); in critically ill patients, more rapid dosage acceleration may be warranted [eg, &ge;0.5 mg/kg daily dose increase; others have initiated at target dose for life-threatening infection (CDC, 2009)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance dose: 0.25-1 mg/kg/dose once daily; rapidly progressing disease may require short-term use of doses to 1.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ; once therapy has been established, amphotericin B may be administered on an every-other-day basis at 1-1.5 mg/kg/dose in some cases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intrathecal, intraventricular, or intracisternal (preferably into the lateral ventricles through a cisternal Ommaya reservoir): 25-100",
"     <b>",
"      mcg",
"     </b>",
"     every 72 hours; increase to 500",
"     <b>",
"      mcg",
"     </b>",
"     as tolerated (Chiou, 1994; Murphy, 2000;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Irrigation, bladder: 50",
"     <b>",
"      mcg",
"     </b>",
"     /mL solution, administered as either a continuous irrigation or as an intermittent irrigation 3 times per day with a dwell time of 60-90 minutes (Fisher, 2011; Gubbins, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Aspergillosis:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis, immunocompromised: Intranasal: 7 mg amphotericin B in 7 mL sterile water was placed in a De Vilbiss atomizer and the aerosolized solution was instilled intranasally to each nostril 4 times daily delivering an average of 5 mg amphotericin/",
"     <b>",
"      day",
"     </b>",
"     to reduce the frequency of invasive aspergillosis in neutropenic patients (Jeffery, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment, HIV-exposed/-positive: I.V.: 1-1.5 mg/kg/dose once daily for &ge;12 weeks; duration should be individualized based upon clinical response (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Blastomycosis",
"      </i>",
"      (independent of HIV status), moderately severe to severe disease:",
"     </b>",
"     I.V.: 0.7-1 mg/kg/dose once daily as initial therapy for 1-2 weeks, followed with oral itraconazole for a total of 12 months (Chapman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Candidiasis; treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Non-HIV-exposed/-positive",
"     </i>",
"     (Pappas, 2009): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Invasive: 0.5-1 mg/kg/dose once daily; duration of therapy dependent upon severity and site of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Urinary tract infections:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Prophylaxis, urologic procedures: I.V.: 0.3-0.6 mg/kg daily for several days before and after procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Asymptomatic (high-risk patients): I.V.: 1 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Symptomatic: 0.3-0.6 mg/kg/dose once daily; duration for 1-7 days for symptomatic cystitis, 14 days for pyelonephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      HIV-exposed/-positive",
"     </i>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Invasive: I.V.: 0.5-1.5 mg/kg/dose once daily; after fever resolution and stabilization, may decrease dose to 1.5 mg/kg once every other day; for candidemia, continue treatment for 2-3 weeks after last positive blood culture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Esophageal: I.V.: 0.3-0.5 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oropharyngeal, refractory: I.V.: 0.3-0.5 mg/kg/day once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Coccidioidomycosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Non-HIV-exposed/-positive",
"     </i>",
"     (Galgiani, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Disseminated (non-CNS) disease: I.V. 0.5-1.5 mg/kg/dose every day or every other day; with or without concomitant azole antifungal; duration determined by clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CNS  disease: Intrathecal: 0.1-1.5 mg/dose; frequency ranging from daily to weekly (with or without concomitant azole therapy); initiate at a low dose and increase until intolerance  (eg, severe vomiting, exhaustion, or transient dose-related mental status changes); duration determined by clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Pulmonary disease, diffuse: I.V. 0.5-1.5 mg/kg/dose every day or every other day for several weeks, followed by an oral azole antifungal for a total length of therapy &ge;12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      HIV-exposed/-positive:",
"     </i>",
"     I.V.: 0.5-1 mg/kg/dose once daily until clinical improvement; minimum of several weeks of therapy (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cryptococcal disease (independent of HIV status)",
"     </b>",
"     (CDC, 2009; Perfect, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CNS disease: I.V.: 0.7-1 mg/kg/dose once daily plus flucytosine;",
"     <b>",
"      Note:",
"     </b>",
"     Minimum 2-4-week induction, followed by consolidation and chronic suppressive therapy; may increase amphotericin dose to 1.5 mg/kg/day if flucytosine is not tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Disseminated (non-CNS disease) or severe pulmonary disease: I.V.: 0.7-1 mg/kg/dose once daily with or without flucytosine; duration of therapy depends on the site and severity of the infection and clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Histoplasma:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Non-HIV-exposed/-positive:",
"     </i>",
"     Severe disseminated (non-CNS) or pulmonary disease: 0.7-1 mg/kg/dose once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Minimum 1-2-week induction, followed by consolidation therapy (Wheat, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      HIV-exposed/-positive:",
"     </i>",
"     CNS or severe disseminated disease: I.V.: 0.7-1 mg/kg/dose once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Minimum 1-2-week induction, longer if clinical improvement delayed or 4-6 weeks if CNS involved; followed by consolidation therapy;  conventional amphotericin B is an alternative therapy, lipid formulations are preferred (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Peritonitis (CAPD):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intraperitoneal, dialysate: Children: 0.5-2  mg per liter of dialysate; either with or without low-dose I.V. amphotericin B therapy (Manley, 2000; Raajimakers, 2007; Warady, 2000a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 1 mg/kg dose once daily (Warady, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Test dose:",
"     </b>",
"     I.V.: 0.1 mg/kg/dose to a maximum of 1 mg; infuse over 20-60 minutes; an alternative method to the 0.1 mg/kg test dose is to initiate therapy with 0.25 mg/kg amphotericin administered over 6 hours; frequent observation of the patient and assessment of vital signs during the first several hours of the infusion is recommended; many clinicians believe a test dose is unnecessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General dosing, susceptible infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 0.25-0.5 mg/kg/dose once daily; gradually increase daily, usually in 0.25 mg/kg increments until the desired daily dose is reached (maximum daily dose: 1.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ); in critically ill patients, more rapid dosage acceleration may be warranted (eg, &ge;0.5 mg/kg daily dose increase)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance dose: 0.25-1 mg/kg/dose  once daily; rapidly progressing disease may require short-term use of doses to 1.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ; once therapy has been established, amphotericin B may be administered on an every-other-day basis at 1-1.5 mg/kg/dose in some cases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intrathecal, intraventricular, or intracisternal (preferably into the lateral ventricles through a cisternal Ommaya reservoir): Limited data available; some dosing based on experience in older pediatric patients: 25-100",
"     <b>",
"      mcg",
"     </b>",
"     every 48-72 hours; increase to 500",
"     <b>",
"      mcg",
"     </b>",
"     as tolerated (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Irrigation, bladder: 50",
"     <b>",
"      mcg",
"     </b>",
"     /mL solution, administered as either a continuous irrigation or as an intermittent irrigation administered 3 times per day with a dwell time of 60-90 minutes (Fisher, 2011; Gubbins, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Aspergillosis:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis; immunocompromised: Intranasal: 7 mg amphotericin B in 7 mL sterile water was placed in a De Vilbiss atomizer and the aerosolized solution was instilled intranasally to each nostril 4 times daily delivering an average of 5 mg amphotericin/",
"     <b>",
"      day",
"     </b>",
"     to reduce the frequency of invasive aspergillosis in neutropenic patients (Jeffery, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment; HIV-exposed/-positive: I.V.: 1-1.5 mg/kg/dose once daily for &ge;12 weeks; duration should be individualized based upon clinical response (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Blastomycosis",
"      </i>",
"      (independant of HIV status), moderately severe to severe disease:",
"     </b>",
"     I.V.: 0.7-1 mg/kg/dose once daily as initial therapy for 1-2 weeks, followed with oral itraconazole for a total of 12 months (Chapman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Candidiasis:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Non-HIV-exposed/-positive",
"     </i>",
"     (Pappas 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Invasive: I.V.: 0.5-1 mg/kg/dose once daily; duration of therapy dependent upon severity and site of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Urinary tract infections:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Prophylaxis, urologic procedures: I.V.: 0.3-0.6 mg/kg daily for several days before and after procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Asymptomatic (high-risk patients): I.V.: 1 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Symptomatic: I.V.: 0.3-0.6 mg/kg/dose once daily; duration for 1-7 days for symptomatic cystitis, 14 days for pyelonephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      HIV-exposed/-positive",
"     </i>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Esophageal: I.V.: 0.3-0.6 mg/kg/dose once daily for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oropharyngeal, refractory: I.V.: 0.3 mg/kg/dose once daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Coccidioidomycosis:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Non-HIV-exposed/-positive",
"     </i>",
"     (Galgiani, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Disseminated (non-CNS) disease: I.V.: 0.5-1.5 mg/kg/dose every day or every other day; with or without concomitant azole antifungal; duration determined by clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CNS disease: Intrathecal: 0.1-1.5 mg/dose; frequency ranging from daily to weekly (with or without concomitant azole therapy); initiate at a low dose and increase until intolerance is noted (eg, severe vomiting, exhaustion, or transient dose-related mental status changes); duration determined by clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Pulmonary disease, diffuse: I.V.: 0.5-1.5 mg/kg/dose every day or every other day for several weeks, followed by an oral azole antifungal for a total length of therapy &ge;12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      HIV-exposed/-positive:",
"     </i>",
"     Non-CNS disease: I.V.: 0.7-1 mg/kg/dose once daily until clinical improvement (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cryptococcal disease (independent of HIV status):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CNS disease: I.V.: 0.7-1 mg/kg/dose once daily plus flucytosine;",
"     <b>",
"      Note:",
"     </b>",
"     Minimum 2-week induction, followed by consolidation and chronic suppressive therapy (CDC, 2009a; Perfect, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Disseminated (non-CNS disease) or severe pulmonary disease: I.V.: 0.7-1 mg/kg/dose once daily with or without flucytosine; duration of therapy depends on the site and severity of infection and clinical response (Perfect, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Histoplasma:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Non-HIV-exposed/-positive:",
"     </i>",
"     Severe disseminated (non-CNS) or pulmonary disease:  I.V.: 0.7-1 mg/kg/dose once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Minimum 1-2-week induction, followed by consolidation therapy (Wheat, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      HIV-exposed/-positive:",
"     </i>",
"     Severe disseminated disease: I.V.: 0.7 mg/kg/dose once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Minimum 2-week induction, longer if clinical improvement delayed; followed by consolidation therapy; conventional amphotericin B is an alternative therapy, lipid formulations are preferred (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Leishmaniasis, visceral (HIV-exposed/-positive):",
"     </b>",
"     I.V.: 0.5-1 mg/kg/dose once daily for a total cumulative dose of 1500-2000 mg (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Penicilliosis, acute infection (HIV-exposed/-positive):",
"     </b>",
"     I.V.: 0.6 mg/kg/dose once daily for 2 weeks, followed by 10 weeks of oral itraconazole (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Peritonitis (CAPD):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intraperitoneal, dialysate: 0.5-2  mg per liter of dialysate, either with or without low-dose I.V. amphotericin B therapy (Manley, 2000; Raajimakers, 2007; Warady, 2000a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 1 mg/kg dose once daily (Warady, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Test dose:",
"     </b>",
"     I.V.: 1 mg infused over 20-30 minutes. Many clinicians believe a test dose is unnecessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Susceptible fungal infections:",
"     </b>",
"     I.V.: 0.3-1.5 mg/kg/dose once daily; 1-1.5 mg/kg over 4-6 hours every other day may be given once therapy is established; aspergillosis, rhinocerebral mucormycosis, often require 1-1.5 mg/kg/day; maximum daily dose: 1.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Peritoneal dialysis (PD):",
"     </b>",
"     Administration in dialysate: 1-2 mg per liter of dialysate, either with or without low-dose I.V. amphotericin B (a total dose of 2-10 mg/kg given over 7-14 days). Precipitate may form in ionic dialysate solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Infants, Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If renal dysfunction is due to the drug, the daily total can be decreased by 50% or the dose can be given every other day. I.V. therapy may take several months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal replacement therapy: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis or CRRT.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as desoxycholate: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intrathecal: Dilute dose in 0.5-2 mL of D",
"     <sub>",
"      5",
"     </sub>",
"     W;  use only preservative-free ingredients (Klaus, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Amphotericin B is administered by I.V. infusion over 2-6 hours; infuse at a final concentration not to exceed 0.1 mg/mL through a peripheral venous catheter; in patients unable to tolerate a large fluid volume, amphotericin B at a final concentration not to exceed 0.5 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or D",
"     <sub>",
"      10",
"     </sub>",
"     W may be administered through a central venous catheter; an in-line filter (&gt;1 micron mean pore diameter) may be used for administration (Kintzel, 1992).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F134716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     Solution:  Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     R, LR, R, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aldesleukin, amiodarone, tacrolimus, teniposide, thiotepa, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amifostine, Aminosyn&reg; II, amsacrine, anidulafungin, aztreonam, bivalirudin, caspofungin, cefepime, dexmedetomidine, docetaxel, doxorubicin liposomal, enalaprilat, etoposide phosphate, fenoldopam, filgrastim, fludarabine, FreAmine&reg; III, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, melphalan, meropenem, ondansetron, paclitaxel, pantoprazole, pemetrexed, piperacillin/tazobactam, propofol, tigecycline, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cefpirome, cisatracurium, doripenem, fluconazole, foscarnet, magnesium sulfate, remifentanil, sargramostim.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Reconstitute only with SWI without preservatives; do not use bacteriostatic water; benzyl alcohol, sodium chloride, or other electrolyte solutions may cause precipitation; reconstituted vials are stable protected from light for 24 hours at room temperature and 1 week refrigerated. Can be further diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, up to D",
"     <sub>",
"      20",
"     </sub>",
"     W, and protected from light; parenteral admixtures are stable for 24 hours at room temperature and 2 days under refrigeration; irrigating solutions should be diluted in sterile water. Short-term exposure (&lt;24 hours) to light during I.V. infusion does",
"     <b>",
"      not",
"     </b>",
"     appreciably affect potency",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of severe systemic infections and central nervous system infections caused by susceptible fungi, such as",
"     <i>",
"      Candida",
"     </i>",
"     species,",
"     <i>",
"      Histoplasma capsulatum",
"     </i>",
"     ,",
"     <i>",
"      Cryptococcus neoformans",
"     </i>",
"     ,",
"     <i>",
"      Aspergillus",
"     </i>",
"     species,",
"     <i>",
"      Blastomyces dermatitidis",
"     </i>",
"     ,",
"     <i>",
"      Torulopsis glabrata",
"     </i>",
"     , and",
"     <i>",
"      Coccidioides immitis",
"     </i>",
"     [FDA approved in pediatric patients (age not specified) and adults]; has also been used for fungal peritonitis; irrigant for bladder fungal infections; used in fungal infection in patients with bone marrow transplantation, amebic meningoencephalitis, ocular aspergillosis (intraocular injection), and chemoprophylaxis (low-dose I.V.)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F134718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Conventional amphotericin formulations (Amphocin&reg;, Fungizone&reg;) may be confused with lipid-based formulations (AmBisome&reg;, Abelcet&reg;, Amphotec&reg;).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F134715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Systemic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing, hyper-/hypotension, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Arachnoiditis, chills, delirium, fever, headache (less frequent with I.T.), malaise, pain along lumbar nerves (especially I.T. therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, cramping epigastric pain, diarrhea, heartburn, nausea (less frequent with I.T.), vomiting (less frequent with I.T.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukocytosis, normochromic-normocytic anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site with or without phlebitis or thrombophlebitis (incidence may increase with peripheral infusion of admixtures)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Generalized pain, including muscle and joint pain (less frequent with I.T.); paresthesia (especially with I.T. therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Decreased renal function and renal function abnormalities including azotemia, renal tubular acidosis, nephrocalcinosis (&gt;0.1 mg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute liver failure, agranulocytosis, anuria, arrhythmias, bone marrow suppression, bronchospasm, cardiac arrest, cardiac failure, coagulation defects, convulsions, diplopia, dyspnea, eosinophilia, hearing loss, hemorrhagic gastroenteritis, hepatitis, hypersensitivity pneumonitis, increased liver function tests, jaundice, leukoencephalopathy, leukopenia, maculopapular rash, melena, nephrogenic diabetes insipidus, oliguria, peripheral neuropathy, pruritus, pulmonary edema, renal failure, renal tubular acidosis, shock, skin exfoliation, Stevens-Johnson syndrome,  thrombocytopenia, tinnitus, toxic epidermal necrolysis, transient vertigo, ventricular fibrillation, vision changes, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amphotericin B or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the nephrotoxic potential of amphotericin B, other nephrotoxic drugs should be avoided; hydration and sodium repletion prior to administration may reduce the risk of developing nephrotoxicity (Branch, 1988); frequent monitoring of renal function is recommended; use with caution in patients with renal impairment. In adults, patients experiencing moderate to severe nephrotoxicity during conventional amphotericin B treatment had three or more risk factors which included body weight &ge;90 kg, male sex, mean daily amphotericin B dosage &ge;35 mg, chronic kidney disease, or concomitant use of amikacin or cyclosporine (Harbath,1991).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Acute pulmonary reactions have been reported in patients simultaneously receiving intravenous amphotericin B and leukocyte transfusions; separate these infusions temporally as much as possible and monitor pulmonary function. Administer by slow I.V. infusion; rapid infusion has been associated with hypotension, hypokalemia, arrhythmias, and shock. Avoid extravasation; may cause chemical irritation; monitor infusion site; heparin 1 unit/1 mL of infusion solution can be added to reduce phlebitis. Use caution with intraperitoneal administration; use associated with irritation to the peritoneum and abdominal pain; not routinely used unless intolerance to other therapies (Warady, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amphotericin I.V. is used primarily for the treatment of patients with progressive and potentially fatal fungal infections",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; do not  use for noninvasive forms of fungal disease. Verify the product name and dosage if dose exceeds 1.5 mg/kg",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; overdosage may result in cardiorespiratory arrest. Anaphylaxis has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs during administration, the infusion should be immediately discontinued; during the initial dosing, the drug should be administered under close clinical observation. Acute reactions (eg, fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, tachypnea) may occur 1-3 hours after starting an intravenous infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. May premedicate patients who experience mild adverse reactions with acetaminophen and diphenhydramine 30 minutes prior to the amphotericin B infusion; meperidine and ibuprofen may help to reduce fevers and chills; hydrocortisone can be added to the infusion solution to reduce febrile and other systemic reactions. If therapy is stopped for &gt;7 days, restart at the lowest dose recommended and increase gradually. In adults, amphotericin B administration of daily dose by continuous I.V. infusion over 24 hours has shown fewer adverse effects and reduced incidence of nephrotoxicity (Eriksson, 2001; Imhof, 2003; Peleg, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Amphotericin B may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13314057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. No teratogenic or undue systemic toxicity (electrolyte imbalance or renal dysfunction) has been reported in the mother or fetus. Toxic maternal effects are to be expected and must be monitored (Perfect, 2010). Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women. Refer to current guidelines (King, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function (monitor frequently during therapy: Every other day during dose increases and at least weekly, thereafter), electrolytes (especially potassium and magnesium), liver function tests, temperature, PT/PTT, CBC; monitor input and output; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes, etc); blood pressure, temperature, pulse, respiration, I.V. site",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor oral absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Minimal amounts enter the aqueous humor, bile, pericardial fluid, pleural fluid, and synovial fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CNS penetration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preterm neonates (GA: 27.4 &plusmn; 5 weeks): High interpatient variability; 40% to 90% of serum concentrations (Baley, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Pediatric patients (0-18 years): Highly variable; reported range: 0.38-3.99 L/kg (Benson, 1989; Koren, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature neonates (GA: 27.4 &plusmn; 5 weeks): 14.8 hours (range: 5-82 hours) (Baley, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children (4 months to 14 years): 18.1 &plusmn; 6.6 hours (range: 11.9-40.3 hours) (Benson, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adult:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 15-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Terminal phase: 15 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (2% to 5% unchanged); ~40% eliminated over 7-day period and may be detected in urine for up to 8 weeks after discontinued use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance (Benson, 1989):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children (8 months to 9 years): 0.57  &plusmn; 0.152 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents (10-14 years):  0.24 &plusmn; 0.02 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Poorly dialyzed",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baley JE, Meyers C, Kliegman RM, et al, \"Pharmacokinetics, Outcome of Treatment, and Toxic Effects of Amphotericin B and 5-Fluorocytosine in Neonates,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 116(5):791-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/2329429/pubmed\" id=\"2329429\" target=\"_blank\">",
"        2329429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benson JM and Nahata MC, \"Pharmacokinetics of Amphotericin B in Children,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1989, 33(11):1989-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/2610508/pubmed\" id=\"2610508\" target=\"_blank\">",
"        2610508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Branch RA, \"Prevention of Amphotericin B-Induced Renal Impairment. A Review on the Use of Sodium Supplementation,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1988, 148(11):2389-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/3056312/pubmed\" id=\"3056312\" target=\"_blank\">",
"        3056312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-4):1-216. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov/contentfiles/adult_oi.pdf\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov/contentfiles/adult_oi.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman SW, Dismukes WE, Proia LA, et al, \"Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(12):1801-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/18462107/pubmed\" id=\"18462107\" target=\"_blank\">",
"        18462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chiou CC, Wong TT, Lin HH, et al, \"Fungal Infection of Ventriculoperitoneal Shunts in Children,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1994, 19(6):1049-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/7888533/pubmed\" id=\"7888533\" target=\"_blank\">",
"        7888533",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eriksson U, Seifert B, and Schaffner A, \"Comparison of Effects of Amphotericin B Deoxycholate Infused Over 4 or 24 Hours: Randomised Controlled Trial,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2001, 322(7286):579-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/11238151/pubmed\" id=\"11238151\" target=\"_blank\">",
"        11238151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisher JF, Sobel JD, Kauffman CA, et al, \"Candida Urinary Tract Infections-Treatment,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(Suppl 6):S457-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/21498839/pubmed\" id=\"21498839\" target=\"_blank\">",
"        21498839",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galgiani JN, Ampel NM, Blair JE, et al, \"Coccidioidomycosis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(9):1217-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/16206093/pubmed\" id=\"16206093\" target=\"_blank\">",
"        16206093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gubbins PO, McConnell SA, and Penzak SR, \"Current Management of Funguria,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1999, 56(19):1929-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/10554910/pubmed\" id=\"10554910\" target=\"_blank\">",
"        10554910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harbarth S, Pestotnik SL, Lloyd JF, et al, \"The Epidemiology of Nephrotoxicity Associated With Conventional Amphotericin B Therapy,\"",
"      <i>",
"       Am J Med",
"      </i>",
"      , 2001, 111(7):528-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/11705428/pubmed\" id=\"11705428\" target=\"_blank\">",
"        11705428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Imhof A, Walter RB, and Schaffner A, \"Continuous Infusion of Escalated Doses of Amphotericin B Deoxycholate: An Open-Label Observational Study,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(8):943-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/12684904/pubmed\" id=\"12684904\" target=\"_blank\">",
"        12684904",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeffery GM, Beard ME, Ikram RB, et al, \"Intranasal Amphotericin B Reduces the Frequency of Invasive Aspergillosis in Neutropenic Patients,\"",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1991, 90(6):685-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/2042684/pubmed\" id=\"2042684\" target=\"_blank\">",
"        2042684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King CT, Rogers PD, Cleary JD, et al, \"Antifungal Therapy During Pregnancy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1998, 27(5):1151-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/9827262/pubmed\" id=\"9827262\" target=\"_blank\">",
"        9827262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Smith GH, \"Practical Guidelines for Preparing and Administering Amphotericin B,\"",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1992, 49(5):1156-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/1595747/pubmed\" id=\"1595747\" target=\"_blank\">",
"        1595747",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klaus JR, Knodel LC, and Kavanagh RE, \"Administration Guidelines for Parenteral Drug Therapy. Part I: Pediatric Patients,\"",
"      <i>",
"       J Pharm Technol",
"      </i>",
"      , 1989, 5(3):101-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/10318297/pubmed\" id=\"10318297\" target=\"_blank\">",
"        10318297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Lau A, Klein J, et al, \"Pharmacokinetics and Adverse Effects of Amphotericin B in Infants and Children,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1988, 113(3):559-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/3411404/pubmed\" id=\"3411404\" target=\"_blank\">",
"        3411404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ku JH, Kim ME, Jeon YS, et al, \"Urinary Ascites and Anuria Caused by Bilateral Fungal Balls in a Premature Infant,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2004, 89(1):F92-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/14711869/pubmed\" id=\"14711869\" target=\"_blank\">",
"        14711869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mactal-Haaf C, Hoffman M, and Kuchta A, \"Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics,\"",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 2001, 17(2):160-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/11847833/pubmed\" id=\"11847833\" target=\"_blank\">",
"        11847833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manley HJ, Grabe DW, Norcross M, et al, \"Stability of Amphotericin B-Lipid Complex (Abelcet) in Peritoneal Dialysis Solutions,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2000, 20(1):87-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/10716591/pubmed\" id=\"10716591\" target=\"_blank\">",
"        10716591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martinez-Pajares JD, Martinez-Ferriz MC, Moreno-Perez D, et al, \"Management of Obstructive Renal Failure Caused by Bilateral Renal Aspergilloma in an Immunocompetent Newborn,\"",
"      <i>",
"       J Med Microbiol",
"      </i>",
"      , 2010, 59(Pt 3):367-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/19910484/pubmed\" id=\"19910484\" target=\"_blank\">",
"        19910484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy K, Bradley J, and James HE, \"The Treatment of",
"      <i>",
"       Candida albicans",
"      </i>",
"      Shunt Infections,\"",
"      <i>",
"       Childs Nerv Syst",
"      </i>",
"      , 2000, 16(1):4-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/10672422/pubmed\" id=\"10672422\" target=\"_blank\">",
"        10672422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, \"Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Chetchotisakd P, Larsen RA, et al, \"A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of HIV-Associated Cryptococcal Meningitis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(12):1775-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/19441980/pubmed\" id=\"19441980\" target=\"_blank\">",
"        19441980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peleg AY and Woods ML, \"Continuous and 4 h Infusion of Amphotericin B: A Comparative Study Involving High-Risk Haematology Patients,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2004, 54(4):803-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/15308606/pubmed\" id=\"15308606\" target=\"_blank\">",
"        15308606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perfect JR, Dismukes WE, Dromer F, et al, \"Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(3):291-322.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/20047480/pubmed\" id=\"20047480\" target=\"_blank\">",
"        20047480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raaijmakers R, Schr&ouml;der C, Monnens L, et al, \"Fungal Peritonitis in Children on Peritoneal Dialysis,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2007, 22(2):288-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/17111161/pubmed\" id=\"17111161\" target=\"_blank\">",
"        17111161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Antibacterial Drugs Dosage Tables,\" 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012. Available at file://aapredbook.aappublications.org/cgi/content/full",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turcu R, Patterson MJ, and Omar S, \"Influence of Sodium Intake on Amphotericin B-Induced Nephrotoxicity Among Extremely Premature Infants,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2009, 24(3):497-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/19082636/pubmed\" id=\"19082636\" target=\"_blank\">",
"        19082636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warady BA, Schaefer F, Holloway M, et al, \"Consensus Guidelines for the Treatment of Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2000, 20(6):610-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/11216549/pubmed\" id=\"11216549\" target=\"_blank\">",
"        11216549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheat LJ, Freifeld AG, Kleiman MB, et al, \"Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(7):807-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/12/201/abstract-text/17806045/pubmed\" id=\"17806045\" target=\"_blank\">",
"        17806045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12647 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_201=[""].join("\n");
var outline_f0_12_201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7254335\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134687\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045094\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11432526\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045086\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134665\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134650\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045097\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134716\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045089\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045096\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134718\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134715\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045100\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045085\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045084\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298744\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134659\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134661\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314057\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045093\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045083\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045099\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12647\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12647|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=related_link\">",
"      Amphotericin B (conventional): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/30/37348?source=related_link\">",
"      Amphotericin B (conventional): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_12_202="Tinea barbae 1";
var content_f0_12_202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86999%7EDERM%2F87000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86999%7EDERM%2F87000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea barbae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large erythematous papulopustular lesions in the beard area of a patient with",
"    <em>",
"     Trichophyton",
"    </em>",
"    infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea barbae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Follicular pustules and crusted lesions in a patient with tinea barbae.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_202=[""].join("\n");
var outline_f0_12_202=null;
var title_f0_12_203="US features suspic axillary LN";
var content_f0_12_203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ultrasound features of suspicious axillary lymph nodes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Two-dimensional enlargement giving a rounded appearance",
"to the lymph node",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echo-poor central hilus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eccentricity of the nodal cortex",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Sapino A, et al. Br J Cancer 2003; 88:702.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_203=[""].join("\n");
var outline_f0_12_203=null;
var title_f0_12_204="Usual doses oral gc asthma";
var content_f0_12_204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Usual dosages for oral glucocorticoids in asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Oral preparations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Systemic glucocorticoids",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        (Applies to all)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylprednisolone",
"       </td>",
"       <td>",
"        2, 4, 8, 16, 32 mg tablets",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         7.5 to 60 mg daily in a single dose in morning or&nbsp;every other day&nbsp;as needed for control.",
"        </p>",
"        <p>",
"         Short-course \"burst\": to achieve control 40 to 60 mg per day as single dose in morning or two divided doses for 3 to 10 days.",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         For long-term treatment of severe persistent asthma, administer single dose in&nbsp;morning either daily or on alternate days (alternate-day therapy may produce less adrenal suppression).",
"        </p>",
"        <p>",
"         Short courses or \"bursts\" are effective for establishing control when initiating therapy or during a period of gradual deterioration.",
"        </p>",
"        <p>",
"         The burst should be continued until patient achieves 80 percent PEFR personal best or symptoms resolve. This usually requires 3 to 10 days but may require longer. In patients receiving inhaled glucocorticoids, there is no evidence that tapering the dose following improvement prevents relapse.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisolone",
"       </td>",
"       <td>",
"        <p>",
"         5 mg tablets;",
"        </p>",
"        <p>",
"         10, 15, and 30 mg orally disintegrating tablets (ODT)",
"        </p>",
"        <p>",
"         5 mg/5 mL, 10 mg/5 mL, 15 mg/5 mL, and 20 mg/5 mL oral solutions",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisone",
"       </td>",
"       <td>",
"        <p>",
"         1, 2.5, 5, 10, 20,&nbsp;50 mg tablets;",
"        </p>",
"        <p>",
"         5 mg/mL, 5 mg/5 mL oral solutions",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PEFR: peak expiratory flow rate.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_204=[""].join("\n");
var outline_f0_12_204=null;
var title_f0_12_205="Carcinoid survival by stage and site";
var content_f0_12_205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five-year survival rates by carcinoid location (1973-1997)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"9\" width=\"11%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        All stages",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Local stage",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Regional stage",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Distant stage",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        CSS",
"       </td>",
"       <td class=\"subtitle2\">",
"        OS",
"       </td>",
"       <td class=\"subtitle2\">",
"        CSS",
"       </td>",
"       <td class=\"subtitle2\">",
"        OS",
"       </td>",
"       <td class=\"subtitle2\">",
"        CSS",
"       </td>",
"       <td class=\"subtitle2\">",
"        OS",
"       </td>",
"       <td class=\"subtitle2\">",
"        CSS",
"       </td>",
"       <td class=\"subtitle2\">",
"        OS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stomach",
"       </td>",
"       <td class=\"centered\">",
"        75.1",
"       </td>",
"       <td class=\"centered\">",
"        55.3",
"       </td>",
"       <td class=\"centered\">",
"        90.2",
"       </td>",
"       <td class=\"centered\">",
"        69.6",
"       </td>",
"       <td class=\"centered\">",
"        40.4",
"       </td>",
"       <td class=\"centered\">",
"        27.2",
"       </td>",
"       <td class=\"centered\">",
"        18.0",
"       </td>",
"       <td class=\"centered\">",
"        9.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small bowel",
"       </td>",
"       <td class=\"centered\">",
"        76.1",
"       </td>",
"       <td class=\"centered\">",
"        54.6",
"       </td>",
"       <td class=\"centered\">",
"        94.5",
"       </td>",
"       <td class=\"centered\">",
"        70.4",
"       </td>",
"       <td class=\"centered\">",
"        84.4",
"       </td>",
"       <td class=\"centered\">",
"        64.1",
"       </td>",
"       <td class=\"centered\">",
"        51.2",
"       </td>",
"       <td class=\"centered\">",
"        32.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appendix",
"       </td>",
"       <td class=\"centered\">",
"        76.3",
"       </td>",
"       <td class=\"centered\">",
"        65.0",
"       </td>",
"       <td class=\"centered\">",
"        95.6",
"       </td>",
"       <td class=\"centered\">",
"        87.8",
"       </td>",
"       <td class=\"centered\">",
"        80.0",
"       </td>",
"       <td class=\"centered\">",
"        67.6",
"       </td>",
"       <td class=\"centered\">",
"        37.5",
"       </td>",
"       <td class=\"centered\">",
"        26.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon",
"       </td>",
"       <td class=\"centered\">",
"        69.5",
"       </td>",
"       <td class=\"centered\">",
"        41.8",
"       </td>",
"       <td class=\"centered\">",
"        94.1",
"       </td>",
"       <td class=\"centered\">",
"        77.1",
"       </td>",
"       <td class=\"centered\">",
"        72.5",
"       </td>",
"       <td class=\"centered\">",
"        35.3",
"       </td>",
"       <td class=\"centered\">",
"        27.8",
"       </td>",
"       <td class=\"centered\">",
"        4.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectum",
"       </td>",
"       <td class=\"centered\">",
"        87.5",
"       </td>",
"       <td class=\"centered\">",
"        77.8",
"       </td>",
"       <td class=\"centered\">",
"        94.9",
"       </td>",
"       <td class=\"centered\">",
"        86.2",
"       </td>",
"       <td class=\"centered\">",
"        53.7",
"       </td>",
"       <td class=\"centered\">",
"        42.1",
"       </td>",
"       <td class=\"centered\">",
"        14.6",
"       </td>",
"       <td class=\"centered\">",
"        13.1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival rates are all age-adjusted to standard 2000 population.",
"    <div class=\"footnotes\">",
"     CSS: cancer-specific survival; OS: overall survival.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240:117. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_205=[""].join("\n");
var outline_f0_12_205=null;
var title_f0_12_206="Contents: Pediatric medical emergencies";
var content_f0_12_206=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric medical emergencies",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric medical emergencies",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/16/21769\">",
"           Acute viral encephalitis in children and adolescents: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/18/23848\">",
"           Acute viral encephalitis in children and adolescents: Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/17/28951\">",
"           Definition and etiology of fever in neonates and infants (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/37/44633\">",
"           Elevated intracranial pressure in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/8/34950\">",
"           Emergency complications of Hirschsprung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/45/4826\">",
"           Epiglottitis (supraglottitis): Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/16/12553\">",
"           Epiglottitis (supraglottitis): Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28074\">",
"           Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/14/22762\">",
"           Fever without a source in children 3 to 36 months of age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22152\">",
"           Management and evaluation of wide QRS complex tachycardia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/61/31705\">",
"           Peritonsillar cellulitis and abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/61/43992\">",
"           Retropharyngeal infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/38/40550\">",
"           Strategies for the evaluation of fever in neonates and infants (less than three months of age)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-2EFB285117-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f0_12_206=[""].join("\n");
var outline_f0_12_206=null;
var title_f0_12_207="Chondrocalcinosis of knee";
var content_f0_12_207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chondrocalcinosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 282px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain radiograph shows chondrocalcinosis of the knee in a patient with hemochromatosis. There is calcification within the cartilage in the tibiofemoral joint space (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_12_207=[""].join("\n");
var outline_f0_12_207=null;
